胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展

doi:10.16352/j.issn.1001-6325.2022.08.1302

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (8): 1302-1305.doi: 10.16352/j.issn.1001-6325.2022.08.1302

胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展

赵茂宇¹, 李佑美¹, 刘焕云², 毛琦^1*

1.陆军军医大学第二附属医院心内科, 重庆 400037;
2.重庆市两江新区第一人民医院心内科, 重庆 401121

收稿日期:2021-04-15 修回日期:2021-08-13 出版日期:2022-08-05 发布日期:2022-08-01
通讯作者: ^*holygeneral1214@163.com

Research progress of insulin resistance markers in atherogenesis

ZHAO Mao-yu¹, LI You-mei¹, LIU Huan-yun², MAO Qi^1*

1. Department of Cardiology, the Second Affiliated Hospital of Army Medical University,Chongqing 400037;
2. Department of Cardiology, the First People's Hospital of Chongqing Liangjiang New Area, Chongqing 401121, China

Received:2021-04-15 Revised:2021-08-13 Online:2022-08-05 Published:2022-08-01
Contact: ^*holygeneral1214@163.com

摘要/Abstract

摘要： 胰岛素抵抗(IR)是连接代谢紊乱和动脉粥样硬化(AS)的关键枢纽。它在AS的启动和进展中发挥重要作用,其潜在机制涉及复杂的病理生理过程,包括内皮损伤、炎性反应激活及氧化应激。IR标志物显示了代谢风险和AS之间存在的潜在关联,检测IR标志物有利于心血管疾病的管理。

关键词: 胰岛素抵抗, 替代标志物, 动脉粥样硬化

Abstract: Insulin resistance (IR) is the pivotal link between metabolic disorders and atherosclerosis (AS). Insulin resistance plays an important role in the initiation and progression of atherosclerosis, and its underlying mechanism involves complex pathophysiological processes including endothelial injury, inflammatory reaction, and oxidative stress. Insulin resistance markers presented the potential association of metabolic risk with atherosclerosis and the detection of insulin resistance markers may support strategy development for the clinical management of cardiovascular diseases.

Key words: insulin resistance, surrogate markers, atherosclerosis

中图分类号:

R541.4

赵茂宇, 李佑美, 刘焕云, 毛琦. 胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1302-1305.

ZHAO Mao-yu, LI You-mei, LIU Huan-yun, MAO Qi. Research progress of insulin resistance markers in atherogenesis[J]. Basic & Clinical Medicine, 2022, 42(8): 1302-1305.

参考文献 24

[1]	Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development[J]. Nat Rev Endocrinol, 2014, 10:293-302.
[2]	Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease[J]. Cardiovasc Diabetol, 2018, 17:122.doi:10.1186/s12933-018-0762-4.
[3]	Di Pino A, Defronzo RA. Insulin resistance and atherosclerosis:implications for insulin-sensitizing agents[J]. Endocr Rev, 2019, 40:1447-1467.
[4]	Saklayen MG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep, 2018, 20:12.doi:10.1007/s11906-018-0812-z.
[5]	Koren D, Taveras EM. Association of sleep disturbances with obesity, insulin resistance and the metabolic syn-drome[J]. Metabolism, 2018, 84:67-75.
[6]	Bornfeldt KE, Tabas L. Insulin resistance, hyperglycemia, and atherosclerosis[J]. Cell Metab, 2011, 14:575-585.
[7]	Biobaku F, Ghanim H, Batra M, et al. Macronutrient-mediated inflammation and oxidative stress:relevance to insulin resistance, obesity, and atherogenesis[J]. J Clin Endocrinol Metab, 2019, 104:6118-6128.
[8]	Schulman IG. Liver X receptors link lipid metabolism and inflammation[J]. FEBS lett, 2017, 591:2978-2991.
[9]	Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome[J]. Semin Immunopathol, 2018, 40:215-224.
[10]	Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease[J]. Cardiovasc Diabetol, 2018, 17:122.doi:10.1186/s12933-018-0762-4.
[11]	Onyango AN, Claudio C, Cabello-Verrugio C. Cellular stresses and stress responses in the pathogenesis of insulin resistance[J]. Oxid Med Cell Longev, 2018, 2018:4321714-4321727.
[12]	Zhao L, Varghese Z, Moorhead JF, et al. CD36 and lipid metabolism in the evolution of atherosclerosis[J]. Brit Med Bull, 2018, 126:101-112.
[13]	Glatz J, Luiken J. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization[J]. J Lipid Res, 2018, 59:1084-1093.
[14]	Son N, Basu D, Samovski D, et al. Endothelial cell CD36 optimizes tissue fatty acid uptake[J]. J Clin Invest, 2018, 128:4329-4342.
[15]	Deng Y, Li G, Chang D, et al. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases[J]. Clin Chim Acta, 2020, 511:40-46.
[16]	Akboga MK. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome[J]. Anato J Cardiol, 2016, 16:953-958.
[17]	Park HK, Kwak MK, Kim HJ, et al. Linking resistin, inflammation, and cardiometabolic diseases[J]. Korean J Intern Med, 2017, 32:239-247.
[18]	Helfer G, Wu Q. Chemerin:a multifaceted adipokine involved in metabolic disorders[J]. J Endocrinol, 2018, 238:R79-R94.
[19]	Zhang Z, Wang J, Wang H. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus[J]. Exp Ther Med, 2018, 15:2936-2940.
[20]	Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance:past, present and future[J]. Crit Rev Clin Lab Sci, 2015, 52:180-190.
[21]	Ahmad R, Thomas R, Kochumon S, et al. Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity[J]. Immun Inflamm Dis, 2017, 5:318-335.
[22]	Gong Z, Zhang X, Su K, et al. Deficiency in AIM2 induces inflammation and adipogenesis in white adipose tissue leading to obesity and insulin resistance[J]. Diabetologia, 2019, 62:2325-2339.
[23]	Akbarzadeh M, Eftekhari MH, Dabbaghmanesh MH, et al. Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes[J]. Iran J Immunol, 2013, 10:167-176.
[24]	Bankul A, Mitra P, Suri S, et al. Increased serum IL-18 levels and IL-18R expression in newly diagnosed type 2 diabetes mellitus[J]. Minerva Endocrinol, 2020.doi:10.23736/s0391-1977.20.03271-x.

胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展

Research progress of insulin resistance markers in atherogenesis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	齐梦亚, 李玉秀, 余洁, 张化冰, 许翎岭, 李伟, 平凡. 新确诊糖尿病患者增加运动与降低胰岛素抵抗和心血管危险因素相关[J]. 基础医学与临床, 2024, 44(7): 984-988.
[2]	陈林木, 黄云秀. 壳寡糖上调SRBI核心岩藻糖基化修饰水平减弱小鼠动脉粥样硬化斑块形成[J]. 基础医学与临床, 2024, 44(4): 474-482.
[3]	余晗俏, 李超, 余育斌, 冯丽娜, 盛晓生, 叶晓霞, 王林燕. 抑制髓样细胞触发受体-1(TREM-1)减轻慢性间歇性低氧诱发的模型小鼠动脉粥样硬化[J]. 基础医学与临床, 2024, 44(3): 368-373.
[4]	张秀丽, 胡孝刚, 莫俊, 陈铃. 冠心宁片减轻大鼠颈动脉粥样硬化斑块损伤[J]. 基础医学与临床, 2024, 44(2): 192-198.
[5]	郭健宏, 王亚玲, 崔文光. 脂蛋白相关磷脂酶A2在急性冠状动脉综合征中作用的研究进展[J]. 基础医学与临床, 2024, 44(1): 103-107.
[6]	宋星明, 哈力沙·艾日肯江, 迪丽胡玛尔·阿布来提, 高颖. 内皮脂肪酶作为冠心病治疗靶点的研究进展[J]. 基础医学与临床, 2023, 43(9): 1443-1447.
[7]	杜丰禾, 刘暴. 血管周围脂肪组织炎性反应促进动脉粥样硬化作用机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 685-689.
[8]	章远谋, 韩康, 夏瑞, 孙文健, 任晓莹, 王砚. 亚临床甲状腺功能减退症对多囊卵巢综合征患者内分泌代谢特征的影响[J]. 基础医学与临床, 2023, 43(4): 641-646.
[9]	刘怡斐, 王鑫宇, 王嘉慧, 杜晓冰, 王途, 赵娟. 尾加压素Ⅱ受体拮抗剂(urantide)减轻动脉粥样硬化大鼠肾脏损伤[J]. 基础医学与临床, 2023, 43(11): 1668-1672.
[10]	朱冰, 王旭. 斑点追踪成像技术在缺血性心脏病诊断中的应用[J]. 基础医学与临床, 2022, 42(9): 1459-1463.
[11]	刘珍竹, 李靖, 何丹, 曲鹏. PI3K信号通路调控动脉粥样硬化发生发展的研究进展[J]. 基础医学与临床, 2022, 42(9): 1428-1432.
[12]	谢思安, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 刘思. VAV1是动脉粥样硬化预后的潜在靶点和生物标志物[J]. 基础医学与临床, 2022, 42(7): 1092-1098.
[13]	许晓双, 闵行, 叶月, 郭梦然, 甄东户. 碘与代谢综合征相关性的研究进展[J]. 基础医学与临床, 2022, 42(6): 979-982.
[14]	郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉. 2型糖尿病心血管并发症发病机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 814-817.
[15]	裘耀扬, 桂家辉, 黄林, 虎学强, 李勤. 血管内光学相干层析成像技术在冠状动脉粥样硬化斑块检测方面的应用[J]. 基础医学与临床, 2022, 42(3): 360-365.